Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0004352 (
autism
)
32,579
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Vasoactive intestinal peptide
(
VIP
) mediates important events during the development of the nervous system.
VIP
can stimulate neuronogenesis as well as differentiation and neurite outgrowth; it can promote the survival of neurons and assist in neuronal repair; it is also anti-inflammatory and can modulate immune responses. In addition,
VIP
is necessary for the normal growth and development of the early postimplantation mouse embryo during the period when the major embryonic events are neural tube formation, neuronogenesis and expansion of the vascular system. Receptors for
VIP
appear during early postimplantation embryogenesis in the rodent and exhibit changing localization patterns throughout the development of the brain. During embryogenesis, unregulated
VIP
may have major and permanent consequences on the formation of the brain and may be a participating factor in disorders of neurodevelopment.
VIP
has been linked to
autism
, Down syndrome and fetal alcohol syndrome. This paper will review the role of
VIP
in neurodevelopment, its known involvement in neurodevelopmental disorders and propose ways in which
VIP
might be of therapeutic value.
...
PMID:Vasoactive intestinal peptide in neurodevelopmental disorders: therapeutic potential. 1743 Jan 71
Vasoactive intestinal peptide
(
VIP
) is a regulator of rodent embryogenesis during the period of neural tube closure.
VIP
enhanced growth in whole cultured mouse embryos; treatment with a
VIP
antagonist during embryogenesis inhibited growth and development.
VIP
antagonist treatment during embryogenesis also had permanent effects on adult brain chemistry and impaired social recognition behavior in adult male mice. The neurological deficits of
autism
appear to be initiated during neural tube closure and social behavior deficits are among the key characteristics of this disorder that is more common in males and is frequently accompanied by mental retardation. The current study examined the blockage of
VIP
during embryogenesis as a model for the behavioral deficits of
autism
. Treatment of pregnant mice with a
VIP
antagonist during embryonic days 8 through 10 had no apparent effect on the general health or sensory or motor capabilities of adult offspring. However, male offspring exhibited reduced sociability in the social approach task and deficits in cognitive function, as assessed through cued and contextual fear conditioning. Female offspring did not show these deficiencies. These results suggest that this paradigm has usefulness as a mouse model for aspects of
autism
as it selectively impairs male offspring who exhibit the reduced social behavior and cognitive dysfunction seen in
autism
. Furthermore, the study indicates that the foundations of some aspects of social behavior are laid down early in mouse embryogenesis, are regulated in a sex specific manner and that interference with embryonic regulators such as
VIP
can have permanent effects on adult social behavior.
...
PMID:Vasoactive intestinal peptide antagonist treatment during mouse embryogenesis impairs social behavior and cognitive function of adult male offspring. 1752 30
Vasoactive intestinal peptide
(
VIP
) regulates growth and development during the early postimplantation period of mouse embryogenesis. Blockage of
VIP
with a
VIP
antagonist during this period results in growth restriction, microcephaly, and developmental delays. Similar treatment of neonatal rodents also causes developmental delays and impaired diurnal rhythms, and the adult brains of these animals exhibit neuronal dystrophy and increased
VIP
binding. These data suggest that blockage of
VIP
during the development of the nervous system can result in permanent changes to the brain. In the current study, pregnant mice were treated with a
VIP
antagonist during embryonic days 8 through 10. The adult male offspring were examined in tests of novelty, paired activity, and social recognition. Brain tissue was examined for several measures of chemistry and gene expression of
VIP
and related compounds. Glial cells from the cortex of treated newborn mice were plated with neurons and examined for
VIP
binding and their ability to enhance neuronal survival. Treated adult male mice exhibited increased anxiety-like behavior and deficits in social behavior. Brain tissue exhibited regionally specific changes in
VIP
chemistry and a trend toward increased gene expression of
VIP
and related compounds that reached statistical significance in the
VIP
receptor, VPAC-1, in the female cortex. When compared to control astrocytes, astrocytes from treated cerebral cortex produced further increases in neuronal survival with excess synaptic connections and reduced
VIP
binding. In conclusion, impaired
VIP
activity during mouse embryogenesis resulted in permanent changes to both adult brain chemistry/cell biology and behavior with aspects of
autism
-like social deficits.
...
PMID:Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry. 1772 25